DUPIXENT MyWayGet information about DUPIXENT MyWay, a program with personalized nursing and coverage support.Explore Resources
Connect With a RepHave questions about DUPIXENT? Get answers from a representative.Request a Visit
Frequently Asked QuestionsHave questions? Get answers to some of the most commonly asked questions.Get Answers
EASI, Eczema Area and Severity Index; IGA, Investigator’s Global Assessment; NRS, numerical rating scale; Q2W, once every 2 weeks; TCS, topical corticosteroids.
Reference:
References:
DUPIXENT Prescribing Information. October 2018.
Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2
Investigators. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med.
2016;375(24):2335-2348.
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of
moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (Liberty AD
Chronos): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet.
2017;389(10086):2287-2303.
Data on file, Regeneron Pharmaceuticals, Inc.
Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive activation of TH2/TH22 cytokines and
selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin
Immunol. 2012:130(6):1344-1354.
DUPIXENT Prescribing Information. October 2018.
Wei W, Anderson P, Gadkari A, et al. Extent and consequences of inadequate disease control among
adults with atopic dermatitis. J Dermatol. 2018;45(2):150-157.
DUPIXENT Prescribing Information. October 2018.
DUPIXENT Prescribing Information. October 2018.
Leshem YA, Hajar T, Hanifin JM, Simpson EL. What the Eczema Area and Severity
Index score tells us about the severity of atopic dermatitis: an interpretability study. Br JDermatol. 2015;172(5):1353-1357.
Data on file, Regeneron Pharmaceuticals, Inc.
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of
moderate-to-severe atopic dermatitis with dupilumab and concomitant topical
corticosteroids (Liberty AD Chronos): a 1-year, randomised, double-blinded, placebo-controlled,
phase 3 trial. Lancet. 2017;389(10086):2287-2303.
Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators.
Two
phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med.
2016;375(24):2335-2348.
EASI User Guide. HOME—Harmonising Outcome Measures for Eczema website.
http://www.homeforeczema.org/documents/easi-user-guide-jan-2017-v3.pdf.
Accessed July 11, 2018.
DUPIXENT Prescribing Information. October 2018.
Data on file, Regeneron Pharmaceuticals, Inc.
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of
moderate-to-severe
atopic dermatitis with dupilumab and concomitant topical corticosteroids (Liberty
AD Chronos): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet.
2017;389(10086):2287-2303.
Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators.
Two
phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med.
2016;375(24):2335-2348.
DUPIXENT Prescribing Information. October 2018.
Data on file, Regeneron Pharmaceuticals, Inc.
Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators.
Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med.
2016;375(24):2335-2348.
Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective
study on validity and reliability of the visual analogue scale, numerical rating scale and verbal
rating scale in 471 patients with chronic pruritus. Acta Derm Venereol. 2012;92(5):502-507.
Blauvelt A, de Bruin-Weller M, Gooderham M, et al. Long-term management of moderate-to-severe
atopic dermatitis with dupilumab and concomitant topical corticosteroids (Liberty AD Chronos): a 1-year,
randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389(10086):2287-2303.
DUPIXENT Prescribing Information. October 2018.
Data on file, Regeneron Pharmaceuticals, Inc.
DUPIXENT Prescribing Information. October 2018.
Data on file, Regeneron Pharmaceuticals, Inc.
DUPIXENT Prescribing Information. October 2018.
Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate-to-severe atopic
dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin
Immunol Pract. 2017;5(6):1519-1531.
Data on file, Regeneron Pharmaceuticals, Inc.
Torrelo A, Ortiz J, Alomar A, Ros S, Pedrosa E, Cuervo J. Health-related quality of life, patient
satisfaction, and adherence to treatment in patients with moderate or severe atopic dermatitis
on maintenance therapy: the CONDA-SAT study. Actas Dermosifiliogr. 2013;104(5):409-417.
DUPIXENT Prescribing Information. October 2018.
Gittler JK, Shemer A, Suárez-Fariñas M, et al. Progressive
activation of TH2/TH22 cytokines and selective epidermal proteins characterizes
acute and chronic
atopic dermatitis. J Allergy Clin Immunol. 2012;130(6):1344-1354.